Literature DB >> 22728263

The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology.

Karen A Kurdziel1, Joanna H Shih, Andrea B Apolo, Liza Lindenberg, Esther Mena, Yolanda Y McKinney, Stephen S Adler, Baris Turkbey, William Dahut, James L Gulley, Ravi A Madan, Ola Landgren, Peter L Choyke.   

Abstract

UNLABELLED: We evaluated the kinetics of (18)F-sodium fluoride (NaF) and reassessed the recommended dose, optimal uptake period, and reproducibility using a current-generation PET/CT scanner.
METHODS: In this prospective study, 73 patients (31 patients with multiple myeloma or myeloma precursor disease and 42 with prostate cancer) were injected with a mean administered dose of 141 MBq of (18)F-NaF. Sixty patients underwent 3 sequential sessions of 3-dimensional PET/CT of the torso beginning approximately 15 min after (18)F-NaF injection, followed by whole-body 3-dimensional PET/CT at 2 h. The remaining 13 prostate cancer patients were imaged only at 2 and 3 h after injection. Twenty-one prostate cancer patients underwent repeated baseline studies (mean interval, 5.9 d) to evaluate reproducibility.
RESULTS: The measured effective dose was 0.017 mSv/MBq, with the urinary bladder, osteogenic cells, and red marrow receiving the highest doses at 0.080, 0.077, and 0.028 mGy/MBq, respectively. Visual analysis showed that uptake in both normal and abnormal bone increased with time; however, the rate of increase decreased with time. A semiautomated workflow provided objective uptake parameters, including the mean standardized uptake value of all pixels within bone with SUVs greater than 10 and the average of the mean SUV of all malignant lesions identified by the algorithm. The values of these parameters for the images beginning at approximately 15 min and approximately 35 min were significantly different (0.3% change per minute). Differences between the later imaging time points were not significant (P < 0.01). Repeated baseline studies showed high intraclass correlations (>0.9) and relatively low critical percentage change (the value above which a change can be considered real) for these parameters. The tumor-to-normal bone ratio, based on the maximum SUV of identified malignant lesions, decreased with time; however, this difference was small, estimated at approximately 0.16%/min in the first hour.
CONCLUSION: (18)F-NaF PET/CT images obtained with modest radiation exposures can result in highly reproducible imaging parameters. Although the tumor-to-normal bone ratio decreases slightly with time, the high temporal dependence during uptake periods less than 30 min may limit accurate quantitation. An uptake period of 60 ± 30 min has limited temporal dependence while maintaining a high tumor-to-normal bone ratio.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22728263      PMCID: PMC3474293          DOI: 10.2967/jnumed.111.100883

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  16 in total

1.  Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer.

Authors:  H Schirrmeister; G Glatting; J Hetzel; K Nüssle; C Arslandemir; A K Buck; K Dziuk; A Gabelmann; S N Reske; M Hetzel
Journal:  J Nucl Med       Date:  2001-12       Impact factor: 10.057

2.  Fluorine-18: a new isotope for bone scanning.

Authors:  M BLAU; W NAGLER; M A BENDER
Journal:  J Nucl Med       Date:  1962-07       Impact factor: 10.057

Review 3.  Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate.

Authors:  G M Blake; S J Park-Holohan; G J Cook; I Fogelman
Journal:  Semin Nucl Med       Date:  2001-01       Impact factor: 4.446

4.  18 F-fluoride for bone imaging.

Authors:  M Blau; R Ganatra; M A Bender
Journal:  Semin Nucl Med       Date:  1972-01       Impact factor: 4.446

5.  Whole body skeletal imaging with [18F]fluoride ion and PET.

Authors:  C K Hoh; R A Hawkins; M Dahlbom; J A Glaspy; L L Seeger; Y Choi; C W Schiepers; S C Huang; N Satyamurthy; J R Barrio
Journal:  J Comput Assist Tomogr       Date:  1993 Jan-Feb       Impact factor: 1.826

6.  Human alimentary tract model for radiological protection. ICRP Publication 100. A report of The International Commission on Radiological Protection.

Authors: 
Journal:  Ann ICRP       Date:  2006

7.  OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.

Authors:  Michael G Stabin; Richard B Sparks; Eric Crowe
Journal:  J Nucl Med       Date:  2005-06       Impact factor: 10.057

8.  The use of 18-F for bone scanning.

Authors:  R J French; V R McCready
Journal:  Br J Radiol       Date:  1967-09       Impact factor: 3.039

9.  Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography.

Authors:  H Schirrmeister; A Guhlmann; J Kotzerke; C Santjohanser; T Kühn; R Kreienberg; P Messer; K Nüssle; K Elsner; G Glatting; H Träger; B Neumaier; C Diederichs; S N Reske
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

10.  The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.

Authors:  Einat Even-Sapir; Ur Metser; Eyal Mishani; Gennady Lievshitz; Hedva Lerman; Ilan Leibovitch
Journal:  J Nucl Med       Date:  2006-02       Impact factor: 10.057

View more
  30 in total

1.  The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer.

Authors:  Iain Murray; Sarah J Chittenden; Ana M Denis-Bacelar; Cecilia Hindorf; Christopher C Parker; Sue Chua; Glenn D Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-13       Impact factor: 9.236

Review 2.  Therapy assessment of bone metastatic disease in the era of 223radium.

Authors:  Elba Etchebehere; Ana Emilia Brito; Alireza Rezaee; Werner Langsteger; Mohsen Beheshti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-31       Impact factor: 9.236

3.  Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma.

Authors:  Christos Sachpekidis; Jens Hillengass; Hartmut Goldschmidt; Hoda Anwar; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-09-01

4.  Unusual Soft Tissue Uptake of F-18 Sodium Fluoride in Three Patients Undergoing F-18 NaF PET/CT Bone Scans for Prostate Cancer.

Authors:  Andrew S Hawkins; Brandon A Howard
Journal:  Nucl Med Mol Imaging       Date:  2016-05-16

5.  Coronary Artery PET/MR Imaging: Feasibility, Limitations, and Solutions.

Authors:  Philip M Robson; Marc R Dweck; Maria Giovanna Trivieri; Ronan Abgral; Nicolas A Karakatsanis; Johanna Contreras; Umesh Gidwani; Jagat P Narula; Valentin Fuster; Jason C Kovacic; Zahi A Fayad
Journal:  JACC Cardiovasc Imaging       Date:  2017-01-18

6.  Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT.

Authors:  Eric M Rohren; Elba C Etchebehere; John C Araujo; Brian P Hobbs; Nancy M Swanston; Michael Everding; Tracy Moody; Homer A Macapinlac
Journal:  J Nucl Med       Date:  2015-07-01       Impact factor: 10.057

7.  Molecular image-directed biopsies: improving clinical biopsy selection in patients with multiple tumors.

Authors:  Stephanie A Harmon; Michael J Tuite; Robert Jeraj
Journal:  Phys Med Biol       Date:  2016-10-03       Impact factor: 3.609

8.  Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation.

Authors:  Christos Sachpekidis; J Hillengass; H Goldschmidt; B Wagner; U Haberkorn; K Kopka; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-29       Impact factor: 9.236

9.  Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.

Authors:  Christie Lin; Tyler Bradshaw; Timothy Perk; Stephanie Harmon; Jens Eickhoff; Ngoneh Jallow; Peter L Choyke; William L Dahut; Steven Larson; John Laurence Humm; Scott Perlman; Andrea B Apolo; Michael J Morris; Glenn Liu; Robert Jeraj
Journal:  J Nucl Med       Date:  2016-07-21       Impact factor: 10.057

10.  First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.

Authors:  Morten Persson; Hongguang Liu; Jacob Madsen; Zhen Cheng; Andreas Kjaer
Journal:  Nucl Med Biol       Date:  2013-04-18       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.